Company ProfilePremium

Ultragenyx Pharmaceutical

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ultragenyx Pharmaceutical - Healthcare showcase

Industry

Healthcare

Services

Medicines
U

Ultragenyx Pharmaceutical Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ultragenyx Pharmaceutical Overview

Ultragenyx Pharmaceutical is a biopharmaceutical company. It focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the US. It also focuses on serious, debilitating metabolic, genetic diseases. The company is led by an experienced management team in rare disease therapeutics.

Strategy

Ultragenyx Pharmaceutical is a biopharmaceutical company which focuses on rare and extremely rare genetic diseases with significant medical needs. It also focuses on in-license promising product candidates and retains global commercialization rights, to maximize long term value of its products. It commercializes through patient-focused global organizations for establishing a network of third-party distributors in small markets.

Company Snapshot

$0.13M

Revenue

SWOT Analysis

Strengths

  • Targeting diseases for which the unmet medical need is high
  • Development of new therapies for diseases with limited or no treatment options

Weaknesses

  • History of operating losses
  • Solely dependent on Kyowa Hakko Kirin for the clinical and commercial supply of Crysvita

Opportunities

  • Expansion of product market in untapped markets
  • Pipeline products

Threats

  • Clinical drug development consumes a lot of time and money for genetic disorder drugs

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product Offering

  • Ultragenyx Pharmaceutical
    • Medicines

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 0.1 Mn in 2016 to USD 51.5 Mn in 2018.
Ultragenyx Pharmaceutical — By Business Segment
Series (USD Mn)201620172018
Sales0.12.651.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.